GlassScriptPhysician profile
Simon P Horslen
NPI 1750471645
$17,911.36
in general payments reported to CMS, 2019-2025
8 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what 86% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,996 · 2020: $131 · 2021: $2,800 · 2022: $18.87 · 2023: $6,815 · 2024: $175 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,605 · Food and Beverage: $328 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,605.00 |
| Food and Beverage | $328.24 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $5,996.39 | 2019 | |
| Albireo Pharma, INC. | $4,875.00 | 2023 | Bylvay |
| Alexion Pharmaceuticals, INC. | $4,700.00 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $1,830.00 | 2025 | Terlivaz |
| Mirum Pharmaceuticals, INC. | $328.24 | 2023-2025 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $149.46 | 2020-2022 | |
| Novo Nordisk INC | $32.27 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Horslen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.